VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$401.55

Market cap

$103.72B

P/E Ratio

28.58

Dividend/share

N/A

EPS

$14.05

Enterprise value

$94.08B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The equity has grown by 26% YoY and by 6% from the previous quarter
VRTX's debt is down by 11% YoY and by 2.7% QoQ
Vertex Pharmaceuticals's quick ratio has decreased by 19% YoY and by 3.7% QoQ
The price to earnings (P/E) is 5% more than the last 4 quarters average of 26.6 and 4.7% more than the 5-year quarterly average of 26.8

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
258.31M
Market cap
$103.72B
Enterprise value
$94.08B
Valuations
Price to book (P/B)
5.89
Price to sales (P/S)
10.49
EV/EBIT
21.27
EV/EBITDA
20.43
EV/Sales
9.53
Earnings
Revenue
$9.87B
EBIT
$4.42B
EBITDA
$4.61B
Free cash flow
$3.34B
Per share
EPS
$14.05
Free cash flow per share
$12.95
Book value per share
$68.22
Revenue per share
$38.3
TBVPS
$80.72
Balance sheet
Total assets
$22.73B
Total liabilities
$5.15B
Debt
$724.7M
Equity
$17.58B
Working capital
$10.6B
Liquidity
Debt to equity
0.04
Current ratio
3.99
Quick ratio
3.6
Net debt/EBITDA
-2.09
Margins
EBITDA margin
46.7%
Gross margin
87.2%
Net margin
36.7%
Operating margin
38.3%
Efficiency
Return on assets
17.3%
Return on equity
22.6%
Return on invested capital
69.8%
Return on capital employed
23.1%
Return on sales
44.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
1.84%
1 week
1.05%
1 month
-3.39%
1 year
21.28%
YTD
-1.31%
QTD
-3.94%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$9.87B
Gross profit
$8.61B
Operating income
$3.78B
Net income
$3.62B
Gross margin
87.2%
Net margin
36.7%
The operating margin has decreased by 20% YoY and by 4.7% QoQ
The operating income has declined by 11% year-on-year and by 2.5% since the previous quarter
VRTX's revenue is up by 11% YoY and by 2.2% QoQ
The gross profit has grown by 10% YoY

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
28.58
P/B
5.89
P/S
10.49
EV/EBIT
21.27
EV/EBITDA
20.43
EV/Sales
9.53
The EPS has increased by 8% year-on-year and by 4.3% since the previous quarter
The price to earnings (P/E) is 5% more than the last 4 quarters average of 26.6 and 4.7% more than the 5-year quarterly average of 26.8
The equity has grown by 26% YoY and by 6% from the previous quarter
The stock's price to book (P/B) is 16% less than its 5-year quarterly average of 6.9
VRTX's revenue is up by 11% YoY and by 2.2% QoQ
The price to sales (P/S) is 7% more than the last 4 quarters average of 9.6 and 3% more than the 5-year quarterly average of 10.0

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has declined by 36% year-on-year and by 13% since the previous quarter
VRTX's return on assets is down by 16% year-on-year
The return on equity has declined by 15% year-on-year
The return on sales has declined by 7% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 25% YoY and by 4.6% QoQ
The total liabilities has increased by 22% YoY
VRTX's debt is 96% lower than its equity
The debt to equity fell by 33% YoY and by 20% QoQ
The equity has grown by 26% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.